MannKind Corp. Stock
Price
Target price
€3.19
€3.19
-1.660%
-0.053
-1.660%
€9.13
15.08.25 / Tradegate
WKN: A2DMZL / Symbol: MNKD / Name: MannKind / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
MannKind Corp. Stock
We can see a decrease in the price for MannKind Corp.. Compared to yesterday it has lost -€0.053 (-1.660%).
With 14 Buy predictions and not the single Sell prediction the community is currently very high on MannKind Corp..
With a target price of 9 € there is potential for a 181.95% increase which would mean more than doubling the current price of 3.19 € for MannKind Corp..
So far the community has only identified positive things for MannKind Corp. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of MannKind Corp. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of MannKind Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| MannKind Corp. | -1.660% | 5.416% | -3.710% | -32.573% | -51.043% | -20.230% | 135.311% |
| Krystal Biotech | -0.930% | 7.757% | 0.824% | -27.257% | -15.572% | 59.627% | - |
| Ardelyx Inc. | 1.990% | 13.795% | 31.527% | -4.781% | 2.679% | 437.367% | 7.281% |
| Evolus Inc | -0.930% | 6.000% | -32.484% | -56.198% | -49.524% | -41.436% | 77.733% |
Comments
MannKind Corporation (NASDAQ: MNKD) had its price target lowered by analysts at Royal Bank Of Canada from $8.00 to $7.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for MNKD provided by MarketBeat
MannKind Corporation (NASDAQ: MNKD) had its price target lowered by analysts at Royal Bank Of Canada from $10.00 to $8.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for MNKD provided by MarketBeat
MannKind Corporation (NASDAQ: MNKD) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $9.00 price target on the stock.
Show more
Ratings data for MNKD provided by MarketBeat
News
MannKind (MNKD) Q2 Revenue Rises 6%
MannKind (NASDAQ:MNKD), a biopharmaceutical firm known for its inhaled insulin and pulmonary therapeutics, released its second quarter 2025 earnings on August 6, 2025. The most significant news from
MannKind (MNKD) Q4 2024 Earnings Call Transcript
Image source: The Motley Fool.
MannKind (NASDAQ: MNKD)Q4 2024 Earnings CallFeb 26, 2025, 4:30 p.m. ET
Operator
Source Fool.com